アブストラクト
| Title | NAFLDからMAFLDへ |
|---|---|
| Subtitle | 今月のテーマ (総説) 脂肪肝診療 |
| Authors | 川口巧, 鳥村拓司1) |
| Authors (kana) | |
| Organization | 1)久留米大学医学部内科学講座消化器内科部門 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 118 |
| Number | 9 |
| Page | 805-814 |
| Year/Month | 2021 / 9 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 「要旨」: 近年, International Consensus Panelより脂肪肝の新診断基準, metabolic dysfunction-associated fatty liver disease(MAFLD)が提唱された. 飲酒量によって規定されるnon-alcoholic fatty liver disease(NAFLD)と異なり, MAFLDは, イベント発症や患者予後のリスクである肥満や糖尿病などの代謝異常を組み入れ基準としている. 本稿では, 現代の脂肪肝診療におけるNAFLDの問題点とMAFLDについて概説する. また, MAFLDとNAFLDの比較研究の結果についても合わせて論述する. |
| Practice | 臨床医学：内科系 |
| Keywords | 脂肪肝, 代謝異常, 肥満, 糖尿病, メタボリックシンドローム |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Samuel VT, Shulman GI: Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides. N Engl J Med 381;1866-1869:2019
- 2) Watanabe S, Hashimoto E, Ikejima K, et al: Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 45;363-377:2015
- 3) Watanabe S, Hashimoto E, Ikejima K, et al: Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 50;364-377:2015
- 4) Eguchi Y, Hyogo H, Ono M, et al: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 47;586-595:2012
- 5) Yamamura S, Kawaguchi T, Nakano D, et al: Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees. Hepatol Res 50;199-213:2020
残りの50件を表示する
- 6) Nakahara T, Hyogo H, Yoneda M, et al: Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 49;1477-1484:2014
- 7) Ochi T, Kawaguchi T, Nakahara T, et al: Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS. Sci Rep 7;10146:2017
- 8) Yamamura S, Eslam M, Kawaguchi T, et al: MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40;3018-3030:2020
- 9) Lu FB, Hu ED, Xu LM, et al: The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 12;491-502:2018
- 10) Hirose S, Matsumoto K, Tatemichi M, et al: Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS One 15:e0241770:2020
- 11) Niriella MA, Kasturiratne A, Beddage TU, et al: Metabolic syndrome, but not non-alcoholic fatty liver disease, increases 10-year mortality: A prospective, community-cohort study. Liver Int 40;101-106:2020
- 12) Younossi ZM, Stepanova M, Ong J, et al: Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clin Gastroenterol Hepatol 17;1625-1633.e1:2019
- 13) Eslam M, Sanyal AJ, George J, et al: MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 158;1999-2014.el:2020
- 14) Eslam M, Newsome PN, Sarin SK, et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 73;202-209:2020
- 15) Ludwig J, Viggiano TR, McGill DB, et al: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55;434-438:1980
- 16) Fouad Y, Gomaa A, Semida N, et al: Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol 74;1254-1256:2021
- 17) Mendez-Sanchez N, Arrese M, Gadano A, et al: The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 6;65-72:2021
- 18) Shiha G, Alswat K, Al Khatry M, et al: Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 6;57-64:2021
- 19) Kim Y, Chang Y, Cho YK, et al: Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 17;543-550.e2:2019
- 20) Tada T, Toyoda H, Sone Y, et al: Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 34;2011-2018:2019
- 21) Yang JD, Ahmed F, Mara KC, et al: Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology 71;907-916:2020
- 22) Seko Y, Yano K, Takahashi A, et al: FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 21;171:2019
- 23) Wei JL, Leung JC, Loong TC, et al: Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol 110;1306-1314:quiz 1315:2015
- 24) Kim D, Kim W, Joo SK, et al: Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. J Gastroenterol 55;330-341:2020
- 25) Kawaguchi T, Torimura T: Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients? J Gastroenterol 55;363-364:2020
- 26) Eslam M, Sanyal AJ, George J: Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology 157;590-593:2019
- 27) Miyake T, Kumagi T, Hirooka M, et al: Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease. J Gastroenterol 51;1090-1100:2016
- 28) Ajmera V, Belt P, Wilson LA, et al: Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 16;1511-1520.e5:2018
- 29) Chang Y, Cho YK, Kim Y, et al: Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology 69;64-75:2019
- 30) Kashiwagi K, Yamaguchi A, Shiba S, et al: Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. Alcohol 89;1-7:2020
- 31) Ogawa E, Takayama K, Hiramine S, et al: Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther 52;866-876:2020
- 32) Nirei K, Matsumura H, Kumakawa M, et al: Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci 14;45-52:2017
- 33) Fukushima N, Kuromatsu R, Arinaga-Hino T, et al: Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res 40;911-922:2010
- 34) Lin S, Wang M, Liu Y, et al: Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol 45;101483:2021
- 35) Mak LY, Hui RW, Fung J, et al: Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 73;800-806:2020
- 36) Takahashi A, Arinaga-Hino T, Ohira H, et al: Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open 2;54-58:2018
- 37) Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112;2735-2752:2005
- 38) Yilmaz Y, Byrne CD, Musso G: A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 15;345-352:2021
- 39) Fouad Y, Waked I, Bollipo S, et al: What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int 40;1254-1261:2020
- 40) Tilg H, Effenberger M: From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 17;387-388:2020
- 41) Alem SA, Gaber Y, Abdalla M, et al: Capturing patient expericnce: A qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol 74;1261-1262:2021
- 42) Fouad Y, Elwakil R, Elsahhar M, et al: The NAFLD-MAFLD debate: Eminence vs evidence. Liver Int 41;255-260:2021
- 43) Mendez-Sanchez N, Diaz-Orozco L, Cordova-Gallardo J: Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. J Hepatol 75;221-222:2021
- 44) Shiha G, Korenjak M, Eskridge W, et al: Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 6;73-79:2021
- 45) Spearman CW, Desalegn H, Ocama P, et al: The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J Hepatol 74;1256-1258:2021
- 46) Younossi ZM, Rinella ME, Sanyal AJ, et al: From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology 73;1194-1198:2021
- 47) Lin S, Huang J, Wang M, et al: Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 40;2082-2089:2020
- 48) Huang SC, Su HJ, Kao JH, et al: Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver 15;451-458:2021
- 49) Wai-Sun Wong V, Lai-Hung Wong G, Woo J, et al: Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol S1542-3565(20)31504-4:2020
- 50) Targher G: Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. Liver Int 40;2879-2880:2020
- 51) Huang J, Kumar R, Wang M, et al: MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant? J Hepatol 73;1265-1267:2020
- 52) Niriella MA, Ediriweera DS, Kasturiratne A, et al: Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One 16;e0245762:2021
- 53) Guerreiro GTS, Longo L, Fonseca MA, et al: Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int 15;380-391:2021
- 54) Lee H, Lee YH, Kim SU, et al: Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nation-wide Cohort Study. Clin Gastroenterol Hepatol S1542-3565(20)31717-1:2020
- 55) Sun DQ, Jin Y, Wang TY, et al: MAFLD and risk of CKD. Metabolism 115;154433:2021
